IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway

International Journal of Cancer

Volumn 120, Issue 12, 2007, Pages 2600-2608

  Lin, Ming Tsan ^a   Lin, Been Ren ^a,b   Chang, Cheng Chi ^b   Chu, Chia Yu ^a,b   Su, Hsiang Ju ^b   Chen, Szu Ta ^a   Jeng, Yung Ming ^a   Kuo, Min Liang ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gastric cancer; Interleukin 6; Rho a; Rho kinase; Src

Indexed keywords

EXOENZYME C3; INTERLEUKIN 6; LIPOSOME; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STEROID RECEPTOR COACTIVATOR 1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 34247468418     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22599     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001;94:153-56.
2. Larsson SC, Orsini N, Wolk A. Processed meat consumption and stomach cancer risk: a meta-analysis. J Natl Cancer Inst 2006;98:1078-87.
3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl 2):ii31-ii36.
4. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002;5 (Suppl 1):5-11.
5. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996;5:477-81.
6. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K. Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, et al. Extended lymph-node dissection for gastric cancer. New Engl J Med 1999;340:908-14.
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med 2001;345:725-30.
8. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42.
9. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
10. Ridley AJ, Rho GT. Pases and cell migration. J Cell Sci 2001;114:2713-22.
11. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002;2: 133-42.
12. Kamai T, Arai K, Tsujii T, Honda M, Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001;87:227-31.
13. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632-41.
14. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861-70.
15. Kamai T, Kawakami S, Koga F, Arai G, Takagi K, Arai K, Tsujii T, Yoshida KI. RhoA is associated with invasion and lymph node metastasis in upper urinary tract cancer. BJU Int 2003;91:234-8.
16. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 2004;10 (18 Part 1):6239-47.
17. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspect of interleukin-6. Immunol Today 1990;11:443-9.
18. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 1999;274:23013-19.
19. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001;20:198-208.
20. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003;22:1517-27.
21. Lin MT, Juan CY, Chang KJ, Chen WJ, Kuo ML. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001;22:1947-53.
22. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
23. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005;95:497-505.
24. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991;164:1038-42.
25. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK, Chi CW. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 1996;91:1417-22.
26. Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 2005;8:124-31.
27. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int J Cancer 1999;81:682-4.
28. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997;8:241-52.
29. Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol 1997;25: 1367-77.
30. Ernst M, Gearing DP, Dunn AR. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J 1994;13:1574-84.
31. Fuhrer DK, Yang YC. Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11. Exp Hematol 1996;24:195-203.
32. Laszlo GS, Nathanson NM. Src family kinase-independent signal transduction and gene induction by leukemia inhibitory factor. J Biol Chem 2003;278:27750-7.
33. Hirano T, Kishimoto T. Interleukin-6. In: Sporn MB, ed. Handbook of experimental pharmacology, Vol. 95. Berlin: Springer-Verlag, 1990. 633-65.
34. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
35. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994;29: 423-9.
36. Takeda K, Fujii N, Nitta Y, Sakihara H, Nakayama K, Rikiishi H, Kumagai K. Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/ or -6. Jpn J Cancer Res 1991;82:1299-308.
37. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109:S121-S131.
38. Kanai M, Konda Y, Nakajima T, Izumi Y, Kanda N, Nanakin A, Kubohara Y, Chiba T. Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 2003;22:548-554.
39. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, Inglese M, McLoughlin RM, Jones SA, Topley N, Baumann H, Judd LM et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat Med 2005;11:845-52.
40. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004;20:23-32.
41. Fincham VJ, Unlu M, Brunton VG, Pitts JD, Wyke JA, Frame MC. Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins. J Cell Biol 1996;135:1551-64.
42. Timpson P, Jones GE, Frame MC, Brunton VG. Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr Biol 2001;11:1836-46.
43. Fukuyama T, Ogita H, Kawakatsu T, Fukuhara T, Yamada T, Sato T, Shimizu K, Nakamura T, Matsuda M, Takai Y. Involvement of the c-Src-Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and formation of adherens junctions. J Biol Chem 2005;280: 815-25.
44. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004;117:989-98.
45. Berdeaux RL, Diaz B, Kim L, Martin GS. Active Rho is localized to podosomes induced by oncogenic Src and is required for their assembly and function. J Cell Biol 2004;166:317-23.
46. a13 in pancreatic acini. Biochem Biophys Res Commun 2006;339:271-6.
47. Nozu F, Tsunoda Y, Ibitayo A, Bitar KN, Owyang C. Involvement of RhoA and its interaction with protein kinase C and Src in CCK-stimulated pancreatic acini. Am J Physiol 1999;276:G915-G923.
48. Chang JH, Gill S, Settleman J, Parsons SJ. c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following epidermal growth factor stimulation. J Cell Biol 1995; 130:355-68.